
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.

Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research

Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain

ctDNA testing may help refine surveillance strategy for colorectal cancer
Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy

Promising activity reported for olaparib in advanced biliary tract cancers
Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers

Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed

Quality of Life data in immune oncology trials: from side note to centre stage?
Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment

Atezolizumab and bevacizumab after transarterial chemoembolisation prolongs progression-free survival in unresectable hepatocellular carcinoma
Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE

Combinations show promise in hepatocellular carcinoma populations with poor prognosis
Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion

Givastomig combined with immunochemotherapy shows clinical activity in metastatic gastro-oesophageal adenocarcinomas
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated